FDA approves prostate cancer drug delivery system
The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.
The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.
These new features include a smaller, 21-gauge needle for improved patient comfort, reconstitution without the use of a needle, and a shield covering the needle both before and after drug administration. The system is specifically designed to encourage compliance with OSHA regulations within the medical community.
IC/BPS has more than 1 phenotype: A need for consensus to move forward
September 19th 2024"A global consensus on standardization of terminology, separation of LUTS vs pain for outcome, HL positivity and negativity, markers for disease, and the role of new interventions for local vs systemic therapy is needed," writes Gopal H. Badlani, MD.
